Incidence of BK with Tacrolimus Versus Cyclosporine and Impact of Preemptive Immunosuppression Reduction

By D. Brennan, I. Agha, D. Bohl, M. Schnitzler, K. Hardinger, Mark Lockwood, Stephanie Torrence, R. Schuessler, Tiffany Roby, M. Gaudreault‐Keener and 1 more. American Journal of Transplantation, 2005

684 citations recorded by the source corpus.

Subfields: Animal Science and Zoology, Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/5e46d35bf69eecd44debaa52ca25eac8dc40e4e5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Supporting Tables
2. D. Brennan
3. H. Hirsch
4. C. Drachenberg
5. A. Gaynor
6. F. Ginevri
7. J. Gordon
8. M. Nissen

Citations in the corpus

• KDIGO clinical practice guideline for the care of kidney transplant recipients. (2009, background): “Subsequent AR, biopsyproven, censored for death, graft loss, premature withdrawal 42% 69% Δ27% (13-40) 95% CI poor”
• Polyomavirus-Associated Nephropathy in Renal Transplantation: Interdisciplinary Analyses and Recommendations (2005, background): “An increased risk of tacrolimus-MMF-corticosteroid combinations for BKV replication and PVAN was demonstrated in a prospective study in which the renal allograft recipients were randomized 2:1 to tacrolimus or CsA (I) (18) and in a retrospective histopathology study (II) (29), respectively.”
• Identification of a Novel Polyomavirus from Patients with Acute Respiratory Tract Infections (2007, background): “Louis cohort, urine samples from 200 adult patients participating in a study of polyomavirus infections in kidney transplant recipients were tested [24].”